Exendin-4 is a dipeptidyl peptidase IV (DPP-IV)-resistant glucagon-like peptide 1 (GLP-1) mimetic and its synthetic counterpart, exenatide, is being used in the therapy of type 2 diabetes (T2DM). No information, however, is currently available as for the direct action of exendin-4 on human T2DM islets. In the present study, we exposed pancreatic islets prepared from non-diabetic and T2DM subjects to exendin-4 for 48 h and found that the compound had several, direct beneficial actions on insulin secretion and the expression of genes involved in beta-cell function and differentiation.
|Autori:||LUPI R; MANCARELLA R; DEL GUERRA S; BUGLIANI M; DEL PRATO S; BOGGI U; MOSCA F; FILIPPONI F; MARCHETTI P|
|Titolo:||Effects of exendin-4 on islets from type 2 diabetes patients|
|Anno del prodotto:||2008|
|Digital Object Identifier (DOI):||10.1111/j.1463-1326.2007.00838.x|
|Appare nelle tipologie:||1.1 Articolo in rivista|